News Story Headlines
January 22, 2025
2025 Winter Newsletter
January 22, 2025
Be sure to catch up on the latest happenings in our winter newsletter here!
January 22, 2025
Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema
January 22, 2025
CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced...
November 25, 2024
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
Nov 25, 2024
− Prescription Drug User Fee Act (PDUFA) Date Set for March 23, 2025 −
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 25, 2024– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading...
November 25, 2024
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
11.22.2024 at 7:12 PM EST
– Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function...
November 18, 2024
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
CAMBRIDGE, Mass., Nov. 16, 2024 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive new clinical...